<DOC>
	<DOCNO>NCT02044822</DOCNO>
	<brief_summary>This study evaluate effect treatment idelalisib ( IDELA ) plus rituximab overall response rate ( ORR ) ; onset , magnitude , duration disease control ( include duration response [ DOR ] , progression free survival [ PFS ] , overall survival [ OS ] ) ; minimal residual disease ( MRD ) subject previously untreated chronic lymphocytic leukemia ( CLL ) 17p deletion . In addition , study evaluate safety profile observe combination IDELA rituximab .</brief_summary>
	<brief_title>Efficacy Safety Idelalisib Combination With Rituximab Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Documented diagnosis Bcell CLL , accord International Workshop Chronic Lymphocytic Leukemia 2008 Presence 17p deletion CLL cell demonstrate FISH test No prior therapy CLL corticosteroid disease complication . CLL warrant treatment Presence measurable lymphadenopathy Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Known histological transformation CLL aggressive lymphoma ( ie , Richter transformation ) . Known presence myelodysplastic syndrome . History nonCLL malignancy except follow : malignancy remission without treatment ≥ 5 year prior enrollment , carcinoma situ cervix , adequately treat basal squamous cell skin cancer localize nonmelanoma skin cancer , asymptomatic prostate cancer without know metastatic disease current requirement therapy require hormonal therapy normal prostate specific antigen ≥ 1 year prior enrollment , ductal carcinoma situ ( DCIS ) breast treated lumpectomy alone , adequately treat Stage 1 2 cancer currently complete remission Evidence ongoing systemic bacterial , fungal , viral infection time enrollment Ongoing liver injury History noninfectious pneumonitis . Ongoing inflammatory bowel disease . History prior allogeneic bone marrow progenitor cell solid organ transplantation . Ongoing immunosuppressive therapy corticosteroid . Received last dose study drug another therapeutic clinical trial within 30 day prior enrollment . Prior ongoing clinically significant illness , medical condition , surgical history , physical finding , electrocardiogram ( ECG ) finding , laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>